Replies to post #152025 on Biotech Values

[DewDiligence]

ACHN (-11%) evidently did not impress investors with the HCV update and CC this morning from AASLD:

http://finance.yahoo.com/news/achillion-provides-clinical-hcv-development-115647492.html

ACHN presented little new info—mainly phase-1b monotherapy data for ACH-2684 in cirrhotic patients.

In this fiercely competitive landscape, slow, steady progress is tantamount to losing ground, so the selloff in ACHN’s shares today may be justified.